General CME Information
Physicians (MDs and DOs) may receive CME credit for attending this meeting. Nonphysicians (including nurses and pharmacists) may request a Certificate of Participation, which may enable nonphysicians to apply their meeting participation hours toward re-licensure.
Questions regarding CME may be sent via e-mail.
CME Accreditation Statement
The American Society of Clinical Oncology (ASCO) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
ASCO designates this educational activity for a maximum of 23 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Needs Statement
In an effort to foster an outlet for new research in the multidisciplinary areas of genitourinary cancers, the American Society of Clinical Oncology (ASCO), American Society for Therapeutic Radiology and Oncology (ASTRO) and the Society of Urologic Oncology (SUO) for the first time are providing a forum for disease-oriented research and clinical findings of genitourinary cancers. A study done by the National Cancer Institute (NCI) Office of Education and Special Initiatives (OESI) in the spring of 2005 found that 96% of ASCO member respondents felt that professional organizations should increase efforts to disseminate new research-indicated practices.1 Through this symposium ASCO is looking to close the gap in education specifically for cancer of the prostate, kidney, testis and bladder.
As the most diagnosed cancer in men, there are an estimated 220,000 cases of prostate cancer for 2007.2 Though there is an improved understanding of prostate cancer biology and a high cure rate for localized disease, most men who develop metastases are still destined to die because of the disease. Kidney cancer is the seventh and ninth most diagnosed cancer in males and females, respectively. Based on current rates, 1 in 74 people will be diagnosed with kidney or renal pelvis cancer during their lifetime.3 Currently, 20% of kidney and renal pelvis cancers are diagnosed at a distant stage, the second most common stage of diagnosis. As of early 2004 there were roughly 178,000 men alive with history of testicular cancer. For 2007, an expected 8,000 new cases of cancer of the testis will be detected in theUnited States. Urinary bladder cancer is projected to have 50,040 new cases in 2007, which is the fourth highest cancer for new cases in men.4 More prevalent in men, bladder cancer is estimated to be the eighth highest cancer causing death in men this year.3
A number of recent studies demonstrate that novel treatments may improve the care of patients with genitourinary cancer. New agents including vaccines, monoclonal antibodies, targeted therapies and others create a positive outlook for the future of cancer treatment. To properly identify and manage patients with genitourinary cancer, physicians must have an in-depth understanding of the treatment options and stay abreast of the rapid evolution of genitourinary cancer management.
The Genitourinary Cancers Symposium looks to meet the educational needs of those involved in the care of patients with genitourinary cancer by providing a multidisciplinary forum for the discussion and analysis of current and emerging scientific and therapeutic advances.
1 National Cancer Institute’s Office of Education Special Initiatives. A Study to Determine How to Improve the Dissemination and Implementation of Evidence-Based Practices in Cancer Care: Report of Practitioner Survey Findings. February 2006.
2 American Cancer Society. Cancer Facts & Figures 2007. Atlanta : American Cancer Society; 2007.
3 Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD , http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.
4 Jemal A, Seigel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin 2007;57:43-66.
Target Audience
This multidisciplinary, international symposium is intended for individuals with clinical and/or research interests in the biology, prevention, epidemiology, diagnosis, and multidisciplinary treatment of genitourinary cancers including: medical oncologists, urologists, radiation oncologists, radiologists, pathologists, epidemiologists, pharmacologists and translational-oriented laboratory scientists.
The program can also benefit the nurses, pharmacists, physician assistants, and all other health care professionals involved in clinical care and research in this area.
Learning Objectives
Upon participation in this activity, attendees will be able to:
-
Summarize the current status of screening for genitourinary cancers, including the development of novel molecular markers and diagnostic strategies used in the detection of genitourinary cancers;
-
Utilize appropriate markers and strategies valuable in risk assessment of patients with localized genitourinary cancers;
-
Analyze the advances in multidisciplinary care of genitourinary cancers, specifically the optimal sequencing combination of various therapeutic options in patients with all stages;
-
Incorporate knowledge gained pertaining to advances in genitourinary cancer into management strategies and trial designs to improve patient outcomes;
-
Compare and contrast outcomes for currently used treatment of localized genitourinary cancers and apply appropriate treatments based on individual patient need.
Disclaimer and Unlabelled Usage Statement
The information presented is that of the contributing faculty and does not necessarily represent the views of the American Society of Clinical Oncology (ASCO), American Society for Therapeutic Radiology and Oncology (ASTRO), Society of Urologic Oncology (SUO), and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.
|
